How Patients can Access the on-going Studies

CG Oncology is currently focused on conducting clinical research that evaluates the safety and effectiveness of investigational cretostimogene grenadenorepvec in Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trials program is the primary way for interested patients to access cretostimogene grenadenorepvec. We encourage patients to speak with their healthcare providers about participating in a clinical trial and may also find information on our current clinical studies site.

In circumstances where patients are not eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors, CG Oncology will consider providing a requesting physician with pre-approval access to cretostimogene grenadenorepvec, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met. These conditions include the following:

Requests will be considered on a case-by-case basis. CG Oncology is committed to evaluating all requests in a fair and equitable manner. All requests must be submitted by the patient's treating physician; CG Oncology may require more detailed information in order to fully evaluate a request. The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals and comply with regulatory obligations, including obtaining patient consent, patient monitoring and safety reporting. Each request will be given careful consideration. Physicians seeking pre-approval access for patients with no alternative treatment options should submit their requests to creto.eap@cgoncology.com. We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request.